- Headquarters
- San Diego, California
- Employees
- 51–200
- Founded
- 2013
- Business Model
- B2B
- Website
- tptherapeutics.com
- Total Funding
- $125.0M
- Last Round
- $80.0M Series DOct 2018
- Rounds
- 2
About
Turning Point Therapeutics (TP Therapeutics) was a clinical-stage precision oncology company based in San Diego, California, developing investigational small-molecule targeted therapies for cancer patients. Founded in 2013, the company applied structure-based drug design to engineer next-generation medicines designed to overcome resistance mechanisms that limit the effectiveness of current treatments. Its lead asset Repotrectinib (Augtyro) received FDA approval and the company was acquired by Bristol Myers Squibb in 2022 for approximately $4.1 billion.
Summary
TP Therapeutics is a Biotech company based in San Diego, United States, founded in 2013. It has raised $125.0M in total across 2 rounds, most recently a $80.0M Series D round in Oct 2018. Investors include Lilly Asia Ventures, OrbiMed and SR One.
Tech & App Stack
4 technologies & apps tracked
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Sign up to view the funding chart
Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.
Apr 2019
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...
Avenzo is a San Diego, CA-based biopharma company to in-license and develop the next generation o...
Clinical-stage biopharma developing dual-action biologics that combine targeted therapy and immun...
Novel bicyclic peptides and drug conjugates for cancer
Clinical-stage biopharmaceutical company founded in 2015 developing best-in-class cancer therapeu...
China's leading blood products manufacturer